Related Experiment Video
Updated: Jan 2, 2026
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
Anticancer Activity of ZnO Nanoparticles against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model
Ryosuke Tanino1, Yoshihiro Amano1, Xuexia Tong1
1Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Shimane University, Izumo, Japan.
Abstract:
Small-cell lung cancer, a highly malignant form of lung cancer, often responds to first-line treatments but relapses in most cases with resistance to further treatments. We tested zinc oxide (ZnO) nanoparticles against small-cell lung cancer and other cancer cell lines, in light of reported anticancer effects in vitro Because of a strong safety record, ZnO nanoparticles are frequently used in biomedical research, including in cellular imaging and drug delivery, and have been used for many years in several commercial products such as skin care agents. Strikingly, ZnO nanoparticles were genotoxic against small-cell lung cancer cells, resulting in low viability, even in cells orthotopically grafted onto mouse models. However, the nanoparticles were less cytotoxic against normal lung-derived cells and did not elicit observable adverse effects after intravenous administration. ZnO nanoparticles were also found to induce highly reactive oxygen species and DNA leakage from nuclei. This study is the first comprehensive evaluation of the anticancer effects of ZnO nanoparticles in vitro and in vivo and highlights new therapeutic opportunities against small-cell lung cancer.
Insights
Zinc oxide nanoparticles show potent anticancer effects against small-cell lung cancer, demonstrating genotoxicity and reduced cell viability. These nanoparticles offer a promising therapeutic avenue with minimal toxicity to normal cells.
Area of Science:
- Nanomedicine
- Oncology
- Materials Science
Background:
- Small-cell lung cancer (SCLC) is highly aggressive and frequently develops treatment resistance after initial response.
- Zinc oxide nanoparticles (ZnO NPs) possess a favorable safety profile and are utilized in biomedical applications.
- Previous studies suggest potential in vitro anticancer properties of ZnO NPs.
Purpose of the Study:
- To comprehensively evaluate the in vitro and in vivo anticancer efficacy of ZnO nanoparticles against SCLC.
- To assess the safety and toxicity profile of ZnO NPs in normal lung cells and in vivo models.
Main Methods:
- In vitro cytotoxicity assays on SCLC and normal lung cell lines.
- In vivo studies using orthotopically grafted SCLC mouse models.
- Assessment of reactive oxygen species (ROS) generation and DNA leakage.
- Evaluation of adverse effects following intravenous administration.
Main Results:
- ZnO NPs exhibited significant genotoxicity and reduced viability in SCLC cells.
- SCLC cells grafted in mouse models showed decreased viability upon ZnO NP treatment.
- ZnO NPs demonstrated lower cytotoxicity against normal lung cells compared to SCLC cells.
- Intravenous administration of ZnO NPs did not result in observable adverse effects.
- ZnO NPs induced reactive oxygen species and DNA leakage from SCLC cell nuclei.
Conclusions:
- ZnO nanoparticles present a novel and effective therapeutic strategy against small-cell lung cancer.
- The targeted genotoxicity of ZnO NPs towards SCLC cells, coupled with a good safety profile, highlights their therapeutic potential.
- Further research into ZnO NP-based therapies could lead to improved outcomes for SCLC patients.
